Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001255492 | SCV001431919 | likely pathogenic | Bardet-Biedl syndrome | 2020-08-24 | criteria provided, single submitter | clinical testing | Variant summary: BBS2 c.1166_1169delTCAG (p.Val389AlafsX27) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251488 control chromosomes. To our knowledge, no occurrence of c.1166_1169delTCAG in individuals affected with Bardet-Biedl Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Baylor Genetics | RCV003462837 | SCV004214049 | likely pathogenic | Bardet-Biedl syndrome 2 | 2023-02-01 | criteria provided, single submitter | clinical testing |